Here are the charities the team is supporting:
 | Marc Ronick is supporting:Charcot-Marie-Tooth disease (CMT) is a rare, inherited peripheral neuropathy first identified in 1886 that causes progressive muscle weakness, atrophy, sensory loss, and lifelong challenges with mobility and daily activities. The mission surrounding CMT is to advance new treatments, improve quality of life, and ultimately find a cure. Leading this effort, the CMTA drives research through its STAR program, which has invested nearly $33 million since 2008, fostering collaboration among patients, clinicians, researchers, and industry experts. This coordinated approach has accelerated innovation in areas such as genetic therapies and drug development, bringing promising progress toward effective treatments for those living with CMT.
|
 |
Jonathan Howard is supporting:Final Victory Animal Rescue, founded in May 2017 in West Columbia, South Carolina, is a nonprofit organization dedicated to saving dogs and cats from overcrowded shelters, neglect, and life on the streets, where they often face the threat of euthanasia. The rescue provides animals with a safe, positive environment through spacious runs, regular walks, socialization, and compassionate care to help them recover from trauma and prepare for adoption. With a strong foster network and effective adoption process, the organization has successfully placed more than 5,000 animals into loving forever homes. Final Victory also facilitates both local and East Coast adoptions, operating by appointment to ensure personalized attention for both animals and adopters.
|
 |
Ralph Estep, Jr., is supporting:Glioblastoma (GBM) is the most aggressive and deadly form of brain cancer, with a median survival of about 15 months even with treatment—and only 3–6 months without—while current standard treatments like surgery, radiation, and chemotherapy often extend life at the cost of significantly reduced quality of life. In response, the Glioblastoma Foundation is dedicated to transforming the standard of care by advancing the development of targeted drug therapies tailored to the unique molecular characteristics of each tumor. Recognizing that no single treatment will be sufficient, the foundation supports research into combination therapies designed to disrupt multiple pathways that enable tumor growth and recurrence, offering hope for more effective and personalized treatment options. |